Nav: Home

Breakthrough enables screening millions of human antibodies for new drug discovery

January 17, 2018

LAWRENCE -- A paper just published in Nature Biotechnology outlines a pioneering method of screening a person's diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specifically target foreign viruses and bacteria, and they have been the fastest-growing class of approved drugs in the past several decades.

The new techniques made it easier to discover new antibody drug molecules while also learning more about immune responses to vaccines and infections. These advances could lead to better preventions and treatments of diseases like Ebola, HIV, flu and Epstein-Barr virus.

"These technologies are providing a new window on human immune protection that we have never been able to see before," said co-lead author Brandon DeKosky, assistant professor of chemical & petroleum engineering and pharmaceutical chemistry at the University of Kansas. "They will dramatically accelerate antibody drug development and may also lead to more effective vaccines."

DeKosky said key innovations set the stage for this new research, including the development of protein display systems in the 1990s, improvements to antibody discovery beginning in the 2000s and the development of technologies to identify natively paired antibody sequences in the 2010s. The new paper combines advances in these three technical areas in an entirely new way to achieve large-scale antibody analysis and screening, resulting in several new and highly potent antibodies in the process.

With co-authors including Bo Wang, Andy Ellington and George Georgiou at the University of Texas-Austin and Morgan Timm, Nancy Sullivan and John Mascola at the National Institutes of Health, DeKosky has developed a technology to screen millions of human B cells to rapidly identify the antiviral antibodies that they contain.

"Antibody molecules are encoded by B cells and are assembled from two different genes, called the heavy and light chains," the KU researcher said. "The VH and VL portions -- derived from the heavy and light chains, respectively -- are the sections of an antibody gene that provide specific viral targeting. So, the VH and VL portions are the most important region to focus on for antibody screening and discovery."

Previous efforts in antibody discovery often relied on single-cell cloning, which led to dozens of experimental or approved drug therapies. However, single-cell cloning holds several major drawbacks because of its very high costs and is limited to sampling a tiny fraction of the human antibody inventory.

"Because antibodies are derived from two different genes -- both of which are highly variable and contained within a single B cell -- we need to perform single-cell manipulations en masse to recover the set of complete antibody genes," DeKosky said. "Traditional single-cell cloning is very expensive and time-consuming. The methods described here overcome those limitations and make it possible to screen millions of antibody-producing cells in a single experiment at an academic lab."

Limitations of previous approaches were a major motivating factor leading to the development of the new technology for screening native antibody libraries.

"Non-natural gene pairing has been used in the past because it's so much easier to do, but often the quality of antibodies discovered is not good enough for an effective drug, and the synthetic nature of those antibodies makes it difficult to understand the true human immune response," DeKosky said. "By maintaining native antibody gene pairings throughout our process, we identified antibodies as they occurred naturally. Along the way, we found extremely potent antibodies and learned more about the human immune response to vaccination and natural infection."

Researchers next will apply this new platform technology to find additional promising antibodies that could serve as the basis for drug therapies.

"Our major motivation was to be able to understand human antibody responses in great detail, which is critical for new therapeutic drug discovery and for vaccine design," DeKosky said. "Promising sources to discover new antibodies include donated blood samples from HIV patients with powerful immune responses against the virus, and also individuals who have received vaccines so that we can understand how those vaccines are working. When a potently neutralizing antibody is discovered, it can lead to new vaccine strategies and new therapeutic drug candidates."

Multiple grants and contracts supported the work, including the National Institutes of Health, the intramural research program of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases, Leidos Biomedical Research Inc. and the Defense Threat Reduction Agency.

DeKosky said a large number of students and research trainees were involved in this project, including at UT-Austin, NIH and KU.

"This is a prime example of the synergy between academic research and scientific training, where trainees learn by contributing to a larger scientific project," he said. "This project was several years in the making, and many undergraduates, grad students and postdocs involved have now transitioned to the next stage of their career. Each of us has brought those new skills and ideas along as we transition to different places."

The KU researcher said these technologies are being applied for drug discovery against a broad range of disease targets in academia, government and the private sector.

"In my lab, we are continuing to develop and improve these systems, and also apply them to learn more about immune responses and discover new therapeutics," DeKosky said. "We are extremely excited to apply the technology to a host of exciting research problems here at KU -- so stay tuned!"
-end-


University of Kansas

Related Antibodies Articles:

Researchers discover first human antibodies that work against all ebolaviruses
After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals against all three major disease-causing ebolaviruses.
New method enables creation of better therapeutic antibodies
Researchers from the University of Maryland and Rockefeller University have refined a method to modify an antibody's sugar group structure, which plays a large role in determining an antibody's ability to activate the immune response.
Antibodies as 'messengers' in the nervous system
Antibodies are able to activate human nerve cells within milliseconds and hence modify their function -- that is the surprising conclusion of a study carried out at Human Biology at the Technical University of Munich (TUM).
Turning therapeutic antibodies inside-out to fight cancer
Researchers at the University of California, Riverside have camels and llamas to thank for their development of a new cancer treatment that is highly selective in blocking the action of faulty matrix metalloproteinases (MMPs).
Zika antibodies from infected patient thwart infection in mice
Researchers have identified neutralizing antibodies against Zika virus from an infected patient that fully protected mice from infection, adding to the current arsenal of antibodies in development for much needed antiviral therapies and vaccines.
A review on the therapeutic antibodies for spinal cord injury
Spinal cord injury (SCI) causes long-lasting damage in the spinal cord that leads to paraparesis, paraplegia, quadriplegia and other lifetime disabilities.
Training human antibodies to protect against HIV
During HIV infection, the virus mutates too rapidly for the immune system to combat, but some people produce antibodies that can recognize the virus even two years after infection.
How antiviral antibodies become part of immune memory
Emory scientists probe activated B cells, important for forming immune memory, during flu vaccination and infection and Ebola infection in humans.
Mouse antibodies pinpoint Zika's weak spots
Antibodies that specifically protect against Zika infection have been identified in mice, report Washington University School of Medicine in St.
Antibodies identified that thwart Zika virus infection
Scientists at Washington University School of Medicine in St. Louis have identified antibodies capable of protecting against Zika virus infection, a significant step toward developing a vaccine, better diagnostic tests and possibly new antibody-based therapies.

Related Antibodies Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Bias And Perception
How does bias distort our thinking, our listening, our beliefs... and even our search results? How can we fight it? This hour, TED speakers explore ideas about the unconscious biases that shape us. Guests include writer and broadcaster Yassmin Abdel-Magied, climatologist J. Marshall Shepherd, journalist Andreas Ekström, and experimental psychologist Tony Salvador.
Now Playing: Science for the People

#513 Dinosaur Tails
This week: dinosaurs! We're discussing dinosaur tails, bipedalism, paleontology public outreach, dinosaur MOOCs, and other neat dinosaur related things with Dr. Scott Persons from the University of Alberta, who is also the author of the book "Dinosaurs of the Alberta Badlands".